Navigation Links
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Date:12/12/2013

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 2013 San Antonio Breast Cancer Symposium.  CB-839 is a potent, selective, orally available glutaminase inhibitor that interferes with tumor metabolism and blocks cancer cell growth and survival. 

"Triple-negative breast cancer, which represents 10-20% of all breast cancers, can be aggressive and difficult to treat due to the fact that the current hormonal and HER-2 directed therapies do not work against these tumors.  Recent data indicate that triple-negative tumor growth is driven in part by high glutaminase expression and a reliance on the conversion of glutamine into glutamate to provide fuel for growth.  CB-839 demonstrates potent inhibition of glutaminase and significant anti-tumor activity in triple-negative breast cancer models, both as a single agent and in combination with the standard-of-care drug paclitaxel," said Susan Molineaux, Ph.D., President and Chief Executive Officer of Calithera Biosciences.  "This research also highlights the potential for use of biomarkers to identify patients whose breast cancer is most likely to respond to CB-839 treatment.  We look forward to advancing CB-839 into Phase 1 clinical studies in patients with advanced triple-negative breast cancer and other solid tumors early next year."

The anti-tumor activity of CB-839 was evaluated in a panel of breast tumor cell lines that included both triple-negative breast cancer and hormone receptor-positive subtypes.  Triple-negative breast cancers displayed higher sensitivity to CB-839 treatment, and this sensitivity was correlated with high glutaminase expression relative to tumor cells that were est
'/>"/>

SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Calithera Biosciences Secures $35 Million in Series D Financing
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
9. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
10. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... (HealthDay News) -- Leaving the car at home and getting ... for your health, a new study indicates. Researchers looked ... that 76 percent of men and 72 percent of women ... of women used public transit, and 14 percent of men ... who drove to work weighed more and had higher levels ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Parents and kids across the nation are ... means buying textbooks and arranging after school care, there ... part of the annual re-commitment to your child’s education; ... Association, 27% of students say they experience "extreme stress" ... are stressed by school pressures. The study, Stress in ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
... Resuscitating hopelessly ill patients too slowly to save their ... prolongs death and suffering, according to the November issue ... Jacinta Kelly, from Trinity College Dublin, has called for ... the practice of slow codes and highlighted the need ...
... Ellex Medical Lasers,Limited (ASX: ELX), a global leader ... ultrasound systems, announced today that the initial,results of ... be presented by Peter Hamilton MD, FRCOph at ... which takes place,November 10-13, in New Orleans. Dr. ...
... Amira Pharmaceuticals, a small,molecule pharmaceutical company focused on ... disease linked to the eicosanoid pathway,today announced the ... development. Dr. Raizon-Ounis brings 20 years of ... clinical research & licensing executive with,Roche Palo Alto. ...
... convenience for on-the-go snacking, COLUMBUS, Ohio, ... ),today announced the launch of new Fruitified(TM) ... four,great-tasting flavors: Apple Cinnamon, Blueberry, Banana Nut ... an excellent source of,protein and calcium and ...
... play role in autism, asthma,and other chronic health ... National Autism,Association (NAA) announced today a nationwide initiative ... program created by,the Deirdre Imus Environmental Center for ... to eliminate the serious,dangers posed to children from ...
... to the Third Quarter of 2006- ... During the Quarter-, PRINCETON, N.J., Nov. 1 Orchid ... identity DNA testing,services, today reported its financial results for the ... the third quarter of 2007,compared to $15.7 million for the ...
Cached Medicine News:Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 2Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 2Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 4Health News:Amira Pharmaceuticals Appoints First Vice President of Development 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 3Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 7
... Nebulizer Prefilled 750ML Sterile H 2 O ... with sterile water for inhalation, these humidifier systems ... which makes a round opening for secure attachment ... designed to help prevent particulate from reaching oxygen ...
... 35%-100% FIO2, ,Empty Nebulizer 002002 has ... It has ports for a feed set ... 5007P and 5207 have FIO2 settings adjustable ... slip-on heaters are also available to provide ...
... , One device provides both ... from a single gas source , ... the number of SKUs dedicated to ... inconvenience of double or wye set ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: